A prospective evaluation of treatment with Selective Internal Radiation Therapy (SIR-spheres) in patients with unresectable liver metastases from colorectal cancer previously treated with 5-FU based chemotherapy
Open Access
- 15 October 2005
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in BMC Cancer
- Vol. 5 (1), 132
- https://doi.org/10.1186/1471-2407-5-132
Abstract
Background To prospectively evaluate the efficacy and safety of selective internal radiation (SIR) spheres in patients with inoperable liver metastases from colorectal cancer who have failed 5FU based chemotherapy. Methods Patients were prospectively enrolled at three Australian centres. All patients had previously received 5-FU based chemotherapy for metastatic colorectal cancer. Patients were ECOG 0–2 and had liver dominant or liver only disease. Concurrent 5-FU was given at investigator discretion. Results Thirty patients were treated between January 2002 and March 2004. As of July 2004 the median follow-up is 18.3 months. Median patient age was 61.7 years (range 36 – 77). Twenty-nine patients are evaluable for toxicity and response. There were 10 partial responses (33%), with the median duration of response being 8.3 months (range 2–18) and median time to progression of 5.3 mths. Response rates were lower (21%) and progression free survival shorter (3.9 mths) in patients that had received all standard chemotherapy options (n = 14). No responses were seen in patients with a poor performance status (n = 3) or extrahepatic disease (n = 6). Overall treatment related toxicity was acceptable, however significant late toxicity included 4 cases of gastric ulceration. Conclusion In patients with metastatic colorectal cancer that have previously received treatment with 5-FU based chemotherapy, treatment with SIR-spheres has demonstrated encouraging activity. Further studies are required to better define the subsets of patients most likely to respond.Keywords
This publication has 14 references indexed in Scilit:
- Prospective study of treatment with selective internal radiation therapy spheres in patients with unresectable primary or secondary hepatic malignanciesInternal Medicine Journal, 2005
- The Price Tag on Progress — Chemotherapy for Colorectal CancerNew England Journal of Medicine, 2004
- Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal CancerNew England Journal of Medicine, 2004
- Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor ReceptorJournal of Clinical Oncology, 2004
- Superiority of Oxaliplatin and Fluorouracil-Leucovorin Compared With Either Therapy Alone in Patients With Progressive Colorectal Cancer After Irinotecan and Fluorouracil-Leucovorin: Interim Results of a Phase III TrialJournal of Clinical Oncology, 2003
- Selective internal radiation therapy with 90yttrium microspheres for extensive colorectal liver metastasesJournal of Gastrointestinal Surgery, 2001
- Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancerThe Lancet, 1998
- Hepatic toxicity resulting from cancer treatmentInternational Journal of Radiation Oncology*Biology*Physics, 1995
- REGRESSION OF LIVER METASTASES FOLLOWING TREATMENT WITH YTTRIUM‐90 MICROSPHERESAnz Journal of Surgery, 1992
- Haematogenous metastastic patterns in colonic carcinoma: An analysis of 1541 necropsiesThe Journal of Pathology, 1986